Publication | Closed Access

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

AsthmaAllergyHealth-related QualityAllergy MedicineImmunologyClinical TrialsAllergenMepolizumab Add-on TherapyPharmacotherapyEosinophilic DisorderImmunotherapyMedicinePhase 3B